Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01092195
Other study ID # 100083
Secondary ID 10-H-0083
Status Completed
Phase Phase 1
First received
Last updated
Start date June 2, 2010
Est. completion date July 19, 2016

Study information

Verified date July 2018
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background:

- Gardasil , a recently approved vaccine for the sexually transmitted human papillomavirus (HPV), provides immunity to four types of HPV that are associated with genital warts and cervical, vaginal, and vulvar precancer and cancer. The vaccine has been shown to be highly effective in preventing infection with these HPV types and was approved for use by the Food and Drug Administration.

- More research is needed about the vaccine s ability to induce immunity in individuals with suppressed immune systems, such as those who have had other kinds of cancer treatment such as stem cell transplant. Genital warts, precancer, and cancer have been reported as a late complication after stem cell transplant. Researchers are interested in determining whether the HPV vaccine is safe to give and able to induce immunity in female stem cell transplant recipients, their female donors, and healthy female volunteers.

Objectives:

- To assess the safety and immune response of the HPV vaccine in female recipients of stem cell transplants who are either off or on stable doses of immunosuppression.

Eligibility:

- Females between 18 and 50 years of age who have had allogenic stem cell transplants.

- Healthy female volunteers, including stem cell donors, are also eligible for this study.

Design:

- Participants will be screened with a physical examination, blood and urine tests, and saliva samples, and will be asked to complete a sexual quality of life questionnaire.

- Sexually active participants will also have a routine gynecologic evaluation.

- Participants will receive three HPV vaccinations according to the standard vaccination schedule (with the second and third following 2 and 6 months after the first). Participants will record their daily temperature and any reactions to the vaccine on a vaccine report card for 1 week after each vaccination.

- Participants will have clinic visits for further testing 2, 6, 7, and 12 months after receiving the first HPV vaccine.


Description:

HPV associated genital dysplasia is a complication following hematopoietic allogeneic stem cell transplantation (HSCT). In a recent study from this institution, one third of female transplant recipients had HPV related genital tract dysplasia. The quadrivalent human papillomavirus virus (HPV) (types 6, 11, 16, 18) vaccine (Gardasil ) is now approved for use in females aged 9-26 for the prevention of cervical cancer and, more recently, vulvar and vaginal cancer. In this study, Gardasil will be used in females age 18 years to 50 at least 90 days post stem cell transplant in two study cohorts to determine its safety and immunogenicity in this population, as a first step to reduce post-transplant HPV-related co-morbidity, genital dysplasia and malignancy. The two study cohorts will both be post transplant; one off of immunosuppression (n=24), and one on immunosuppression (n=24). Gardasil will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months. The primary objectives of this study are to determine the safety and immunogenicity of Gardasil in female allogeneic HSCT recipients. A cohort of healthy subjects will also be vaccinated (n=24) and will serve as a control. Immunogenicity studies characterizing the CD4 and CD8 T- cell response, change in antibody titer and cytokine response from baseline to months seven and twelve will be compared in the three cohorts. Additionally, genital exams will be performed to monitor for HPV. Secondary endpoints will characterize sexual function post-transplant and vulvar/vaginal graft-versus-host disease (GVHD). When available, healthy female stem cell donors corresponding to enrolled vaccine recipients will be enrolled (n=10) as part of the healthy cohort and vaccinated to determine whether there are differences in HPV vaccine immunogenicity in a subset of donors and their respective allogeneic, HSCT female recipients.

As stem cell transplant becomes more applicable to the general population with newer transplant techniques allowing for a larger donor pool and as survival improves, problems associated with long term survivorship such as genital dysplasia, will become more prevalent. Vaccine therapy to prevent or eradicate this disease is needed.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date July 19, 2016
Est. primary completion date July 19, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility - INCLUSION CRITERIA:

Female stem cell transplant recipient at least 90 days post stem cell transplant

OR

Female stem cell transplant recipient at least 90 days post HSCT and on immunosuppression

OR

The matched female stem cell transplant donor for an included stem cell transplant recipient

OR

Healthy female subject

Age greater than or equal to 18 years and less than or equal to 50 years

EXCLUSION CRITERIA:

Vaccine Recipient:

Obvious HPV condyloma or obvious severe dysplasia (greater than or equal to CIN II) warranting treatment

History of severe adverse reaction to any components (yeast, eggs, monosodium glutamate or neomycin) of the quadrivalent HPV vaccine.

Untreated or persistent life-threatening infections not controlled by current treatment

Uncontrolled chronic GVHD i.e. highly active eGVHD requiring immediate intervention

Pregnant or breast feeding or unwilling to be abstinent or practice effective contraception during the study period (note: patients who have been rendered infertile with total body irradiation are eligible)

Enrollment in another vaccine clinical trial during the study period

Enrollment of healthy volunteer in a drug clinical trial during the study period

Inability to comprehend the investigational nature of the study and provide informed consent<TAB>

Prior Gardasil or other HPV vaccination

Persistent or recurrent malignancy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Gardasil
3 separate 0.5 ml intramuscular

Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004 Dec;31(12):748-52. — View Citation

Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-63. Review. — View Citation

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Subjects Who Developed Antibody Response to the Vaccine. The percentage of subjects who developed antibody response to the quadrivalent HPV (qHPV) vaccine (HPV - 6/ - 11/ - 16/ - 18). Anti-HPV-6/11/16/18-specific antibody responses using L1 Virus Like Particle (VLP) ELISA were measured in serum. 12 months
See also
  Status Clinical Trial Phase
Completed NCT03641378 - Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT06155188 - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia N/A
Recruiting NCT03562065 - Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord Phase 1/Phase 2
Completed NCT01468935 - Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning
Active, not recruiting NCT03938324 - Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions N/A
Completed NCT04219657 - Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application Phase 1
Not yet recruiting NCT03259217 - Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers Phase 1
Recruiting NCT01189786 - Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection N/A
Recruiting NCT04610359 - Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis Phase 1
Completed NCT05712148 - Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa Phase 1/Phase 2
Recruiting NCT05515497 - BMT4me: Post-HSCT Medication Adherence mHealth App N/A
Completed NCT01984671 - Mobile Pain Coping Skills Training for Stem Cell Transplant Patients N/A
Not yet recruiting NCT06075927 - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT Phase 1/Phase 2
Completed NCT03440775 - Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients N/A
Recruiting NCT02652052 - Hematopoietic Stem Cell Transplant Survivors Study N/A
Not yet recruiting NCT04922970 - Strength Training as Prevention and Treatment of Late Effects in Long-term Survivors of Pediatric HSCT. N/A
Completed NCT04041219 - Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients Phase 4
Completed NCT00656058 - Montelukast to Treat Bronchiolitis Obliterans Phase 2
Recruiting NCT04375579 - Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Completed NCT03859765 - In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients N/A